Medline ® Abstract for Reference 17
of 'Treatment of relapsed or refractory acute lymphoblastic leukemia in adults'
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jain N, O'Brien S, Thomas D, Kantarjian H
Front Biosci (Elite Ed). 2014;6:40. Epub 2014 Jan 1.
Antibody-drug conjugates (ADCs) represent a major advance in the treatment of acute lymphoblastic leukemia (ALL). CD22 expression, seen in majority of patients with B-lineage ALL, is an ideal target for ADCs. Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin. Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing.
Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030.